MRC Molecular Haematology Unit

Professor KJ Patel awarded major European Research Council Advanced Grant

Professor Patel is one of fourteen researchers at the University of Oxford awarded Advanced Grants from the European Research Council (ERC), each worth up to €2.5 million over a period of five years.

Study reveals blood stem cells can ‘remember’ inflammation

Researchers have discovered that some human blood stem cells retain a lasting “memory” of inflammation, a finding that could help explain links between ageing, chronic disease, and blood cancers

Professor Adam Mead joins Oxford Cancer leadership team

Congratulations to Adam Mead, who has been appointed Director of Oxford Cancer. Professor Mead joins Professors Mark Middleton and Tim Elliott in leading Oxford’s interdisciplinary cancer research community.

A chessboard with a single pawn left standing.

DNA-damaging formaldehyde accelerates blood ageing by extinction of stem cells

Researchers from the University of Oxford, the German Cancer Research Center, and Hospital Saint-Louis have uncovered a surprising new way that blood stem cells are lost over time, offering fresh insight into ageing and diseases that affect blood production.

Close-up shot of microscope with metal lens.

Oxford University spinout Dark Blue Therapeutics acquired to advance leukaemia treatment

Oxford University spinout Dark Blue Therapeutics has been acquired by global biotechnology company Amgen in a deal worth up to US$840 million, marking a major milestone for Oxford-led cancer research and innovation. The deal reflects years of collaborative, multidisciplinary work across the University and its partners to translate fundamental research into promising new medicines.

At the MRC Molecular Haematology Unit, we aim to understand how stem cells produce mature blood cells in a healthy context, and how this process is perturbed in common blood disorders.

MRC MHU includes 14 research teams with over 140 scientists who share a common goal, to improve the prognosis of patients with inherited and acquired blood diseases.

About the MRC MHU

Find out more...

MRC MHU Research Groups

Find out more

MRC MHU People

Find out more...

FULL MRC MHU SEMINAR LIST

Find out more

Hands reaching into box filled with jelly pearls. The round pearls represent the different components of the blood.

Public Engagement

Find out more

This is an exciting time for the field of haematology. The -omics revolution is enabling scientists to unravel the complex molecular processes governing biology at unprecedented speed. At the MRC MHU our teams are committed to applying such cutting-edge techniques to better understand the molecular basis of blood diseases, and to develop treatments to improve the lives of patients. - Professor KJ Patel

MRC MHU Director- Professor KJ Patel

Latest publications

CDIN1-Codanin-1 complex defective in congenital dyserythropoietic anaemia type I is an RNA nuclease.

Brolih S. et al, (2026), Nat Commun

Forging New Pathways in Oncology: Strategic Insights from the 17th Annual Frontiers in Cancer Science Conference.

Huang D. et al, (2026), Cancer Res, 86, 3106 - 3108

CAR T cell therapy selectively depletes disease-driving mutant calreticulin cells in xenotransplants and human organoid models of myelofibrosis.

Rampotas A. et al, (2026), Sci Transl Med, 18

TiO2 Alternative Coatings for Ferric Pyrophosphate Premixes: Stability and Bioaccessibility Relative to Ferrous Fumarate

Teichman DL. et al, (2026), Innovative Food Science and Emerging Technologies, 111

VDJ-REMIX: REpertoire Module Identification and eXploration

Amin S. et al, (2026), Bioinformatics, 42

Cookies on this website

MRC Molecular Haematology Unit

Professor KJ Patel awarded major European Research Council Advanced Grant

About the MRC MHU

MRC MHU Research Groups

MRC MHU People

FULL MRC MHU SEMINAR LIST

Public Engagement

MRC MHU Director- Professor KJ Patel

Latest publications

CDIN1-Codanin-1 complex defective in congenital dyserythropoietic anaemia type I is an RNA nuclease.

Forging New Pathways in Oncology: Strategic Insights from the 17th Annual Frontiers in Cancer Science Conference.

CAR T cell therapy selectively depletes disease-driving mutant calreticulin cells in xenotransplants and human organoid models of myelofibrosis.

TiO2 Alternative Coatings for Ferric Pyrophosphate Premixes: Stability and Bioaccessibility Relative to Ferrous Fumarate

VDJ-REMIX: REpertoire Module Identification and eXploration